Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 10/3/23 → 10/3/26 |
Financiación
- Bicara Therapeutics Incorporated: 43.674,00 US$
23-MULTI-60-BT-PMC (BCA101X1101): First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFbeta; Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
- Arnold, Susanne M (PI)